Demant (WILYY)
OTHER OTC:WILYY
Want to see WILYY full AI Analyst Report?
WILYY Stock Chart & Stats
$17.22
$0.87(4.68%)
At close: 4:00 PM EST
$17.22
$0.87(4.68%)
Day’s Range― - ―
52-Week Range$13.80 - $22.17
Previous CloseN/A
Volume404.00
Average Volume (3M)4.00
Market Cap
$7.97B
Enterprise Value$75.00B
Total Cash (Recent Filing)$1.33B
Total Debt (Recent Filing)$20.99B
Price to Earnings (P/E)34.4
Beta0.97
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.52
Shares Outstanding423,506,600
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)4.48
Price to Sales (P/S)1.92
P/FCF Ratio13.87
Enterprise Value/Market Cap9.41
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit4.31
Enterprise Value/Ebitda13.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very High Gross Margins (strong Product Economics)Sustained gross margins near 75% point to durable product-level profitability and pricing power in devices and consumables. That economics provides a structural buffer for the P&L, allowing margin recovery plans and cash generation even if ASPs or mix shift temporarily.
Strong Cash Generation & FCF ConversionHigh free cash flow conversion demonstrates the business converts earnings into liquidity reliably, supporting deleveraging, integration funding and capex without sole reliance on capital markets. That cash generation improves long-term financial flexibility despite recent M&A.
KIND Acquisition Expands Hearing‑care Footprint And Earnings BaseKIND materially scales clinic network (notably Germany), shifting revenue mix toward recurring clinic and service income. The anticipated EBIT contribution and scale synergies strengthen market position and diversify revenue away from pure device cycles, supporting more stable long‑term margins.
Bears Say
Elevated Leverage And Refinancing RiskMaterially higher leverage reduces financial flexibility and raises refinancing risk if cash flow falters. Management paused buybacks and targets deleveraging to 2.0–2.5 within 18–24 months, which constrains capital allocation and leaves the firm sensitive to interest or earnings shocks.
Weakened Operating And Net ProfitabilityDeclining EBIT and net margins indicate rising operating costs, mix shifts or one‑offs that reduce the firm's ability to convert revenue into sustainable profits. Lower profitability hampers deleveraging, limits reinvestment capacity and increases sensitivity to market headwinds.
Structural Market Softness, U.S. Share Loss And FX HeadwindsSofter end‑market growth, U.S. share loss to expanded suppliers and a multi‑hundred‑million DKK FX EBIT headwind are structural risks. Together they depress organic growth potential and make margin recovery and planned deleveraging more challenging if trends persist over multiple quarters.
Demant News
WILYY FAQ
What was Demant’s price range in the past 12 months?
Demant lowest stock price was $13.80 and its highest was $22.17 in the past 12 months.
What is Demant’s market cap?
Demant’s market cap is $7.97B.
When is Demant’s upcoming earnings report date?
Demant’s upcoming earnings report date is Aug 11, 2026 which is in 66 days.
How were Demant’s earnings last quarter?
Demant released its earnings results on Feb 03, 2026. The company reported $0.159 earnings per share for the quarter, beating the consensus estimate of N/A by $0.159.
Is Demant overvalued?
According to Wall Street analysts Demant’s price is currently Overvalued.
Does Demant pay dividends?
Demant does not currently pay dividends.
What is Demant’s EPS estimate?
Demant’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Demant have?
Demant has 423,506,600 shares outstanding.
What happened to Demant’s price movement after its last earnings report?
Demant reported an EPS of $0.159 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.588%.
Which hedge fund is a major shareholder of Demant?
Currently, no hedge funds are holding shares in WILYY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Demant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.03%
12-Months-Change
Fundamentals
Return on Equity
16.06%
Trailing 12-Months
Asset Growth
36.36%
Trailing 12-Months
Company Description
Demant
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
WILYY Company Deck
WILYY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced message: the company delivered solid cash generation, successful product launches (Zeal) and an acquisition that strengthens its Hearing Care footprint, while presenting a clear 2026 growth and profitability roadmap. At the same time, near-term profitability is pressured by a softer hearing aid market (especially in the U.S.), ASP/headwind mix effects, FX impacts, elevated leverage after the KIND acquisition, and planned restructuring/special items. Management expects the cost program and KIND contribution to support margin recovery in 2026, but risks (market softness, competitive pressure and FX) remain.View all WILYY earnings summariesTechnical Analysis
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Steris
―
Zimmer Biomet Holdings
―